🟢 Veraxa Biotech is trading 5% up in pre-market following positive BiTAC-ADC breast cancer model results

Veraxa Biotech is trading at $1.20, up 5.28% in pre-market, reacting to the announcement of its BiTAC-ADC results. - On October 13, 2026, Veraxa Biotech presented first in vivo proof-of-concept data, including significant tumor regression in a breast cancer model after a single dose. - These positive results were unveiled at the 17th World ADC Congress and are confirmed as the likely driver for today's pre-market stock movement.